## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.3% below STRENGTH zone (4.0-10.0%); PEG 4.80 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($81.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends**
- Source: Simply Wall Street | 20260104T130901 | Neutral | Relevance: 100%
- Edwards Lifesciences (NYSE:EW) has seen a decline in its Return on Capital Employed (ROCE) over the last five years, falling from 22% to 14%. Despite this decrease, the company is experiencing revenue growth and reinvesting in its operations, which could lead to future benefits for shareholders. While current total returns to shareholders have been flat, the underlying growth trends suggest potential for recovery, warranting closer observation of the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.8M in recent transactions.
3. Valuation stretched: PEG 4.8x requires aggressive growth execution.

### Catalysts

- Analyst target momentum: 3 raises (avg +7%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.80 signals overvaluation risk, limited margin of safety. Forward P/E 29.3x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Analyst sentiment positive (3 raises, avg +7%, $96 target (+15%)). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.4B |
| Beta | 0.95 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.80 |
| Forward P/E | 29.3 |
| Current P/E | 32.6 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.8% to -1.3% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.28% (CS: 26) | Neutral |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.078x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $84.17
- **Stop Loss:** $81.15 (3.6% risk)
- **Target:** $87.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 285
- **Position Value:** $23,988.45
- **Portfolio %:** 23.99%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*